Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

NCT07747506 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT07747506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07747506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 3, 2026
Completion date
August 1, 2028
Enrollment
2 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

low grade ovarian serous adenocarcinoma, ovarian cancer